Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DAL reports Q3 results on October 9 with analysts pulling back price targets, options traders sitting comfortably on the call side, and short sellers at their lightest positioning in weeks.
The dominant story heading into the print is what the analyst community has done in the past ten days. Target cuts have come from every direction: Bernstein lowered to $100 from $106, Susquehanna to $100 from $105, and Wells Fargo to $100 from $105, all within the last 48 hours, all while keeping positive ratings intact. TD Cowen and BMO Capital trimmed to similar levels earlier in the week. The lone outlier in recent weeks was UBS, which raised its target to $105 on September 24 before cutting back to $99 on September 10 in a prior move. The pattern is consistent: the Street still sees roughly 21% upside from the current $83.66 close, with a mean target near $101, but it is quietly reducing its confidence in the near-term setup. No analyst has turned negative. The consensus remains firmly buy-side. But the direction of travel on targets is unambiguous.
Positioning in the lending market and in options is notably less cautious than the analyst tone would suggest. Short interest has pulled back sharply from its September peak. At the mid-September high, DAL had roughly 27.3 million shares short. That number is now 22.3 million, 3.4% of the free float, and flat on the week. The borrow market is effectively frictionless: availability runs at 1,796% of outstanding short interest, meaning there are nearly 18 times as many shares available to lend as there are shares currently borrowed. Cost to borrow has edged up 36% over the past month to 0.54%, but that is still firmly in the low range for a liquid large-cap name. Options positioning has drifted back toward the call side after a period of heavier put activity through August and early September. The put/call ratio is 0.57, below its 20-day average of 0.66, and the z-score of minus 0.50 places it well within normal territory, leaning bullish without being at an extreme.
The factor picture adds some texture. DAL scores in the 89th percentile on EPS surprise, a strong track record of beating estimates. The 90-day EPS momentum rank is 72, meaning forward estimates have been moving up relative to most names in the universe. The 30-day EPS momentum rank is just 14, however, reflecting the recent run of target cuts and possibly some downward estimate drift. The trailing PE has expanded about 1.2 points over the past month to 11.2x. EV/EBITDA is near 6.9x. These are not demanding multiples for a carrier with DAL's premium revenue mix and balance sheet positioning.
The ownership picture carries one headline worth flagging. Warren Buffett's Berkshire Hathaway filed a Schedule 13G/A in August disclosing an 8.7% stake, up from 6.1% previously. That amendment covers a passive, non-activist position. As always with 13D/G disclosures, the stake reflects the position as last reported around the 5% threshold, and the filing carries no obligation to update unless the holder crosses back below 5%. Still, Berkshire adding roughly 2.6 percentage points to its DAL holding over the course of 2026 is a meaningful endorsement at current valuation levels.
The insider register from August tells a different, more routine story. CEO Edward Bastian, President Peter Carter, and EVP Steven Sear all exercised options and sold the resulting shares in early August, with Bastian's gross sale totalling roughly $19 million at prices near $92.80. These were exercise-and-sell transactions, not discretionary open-market sales, and carry limited signalling value on their own. No open-market purchases appear in the recent record.
What to watch on October 9: whether DAL's Q3 revenue and margin commentary moves the consensus target cluster sitting at $100 to $105, or forces another round of reductions despite the persistently bullish ratings.
See the live data behind this article on ORTEX.
Open DAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
